|
|
|
European Pharmaceutical Contractor
|
Traditionally, the drug industry has been immune to the vagaries of international stock market fluctuations. As I write this letter this immunity is beginning to be removed with 'scandals' depressing share values in both medium-sized companies such as Galen and Elan as well as the 'bellweather' giants such as Merck. That tradition should be usurped in this way is not good news for the CRO industry, any more than it is good news for the companies' shareholders. Pharma companies have always been conservative, even if their science was innovative. Stock price uncertainty will surely breed more conservatism and a reluctance to conduct research out-of-house, lest the company lose control. In just the same way as mega mergers put projects on hold or at risk, so the falling stock prices will tend to have the same effect.
But mega mergers of the type just announced between Pfizer and Pharmacia may not be the way to go. Productivity and efficiency no longer seem to be necessarily related to size, big organisations may become inefficient, if not impossible, to manage. This theme is developed by John Morris of KPMG who believes that there is likely to be a slow down in M&A activity in the near future.
However, M&A is seen as a way of achieving the holy grail of global reach not only in development but also in sales. Ben Coppin at Envisional discusses combined Internet sales and promotion of prescription products as a globalisation route. Although, as he points out, this may only be an acceptable practice if the Internet is somewhat regulated - how this is to be done will remain a challenge.
|
Read full article from PDF >>
|
|
 |
|
| Rate this article |
You must be a member of the site to make a vote. |
|
Average rating: |
0 |
| | | | | |
|
|
 |
Industry Events |
 |
EMBALLAGE 2012
19-22 November 2012, Paris Nord Villepinte, France
EMBALLAGE has clearly delineated sectors to make the decision-maker’s task easier when visiting and to highlight all the industry’s know-how: machinery and packaging for the food and cosmetics sectors, health solutions and luxury packaging and containers, etc. Hence, EMBALLAGE provides a bespoke solution for each industry
More info >> |
|
 |
News and Press Releases |
 |
AMRI Announces Preferred Provider Agreement with BioPontis Alliance LLC
AMRI, a global contract services organization, announced today that it has entered into a preferred provider agreement with BioPontis Alliance LLC. The agreement is aimed at supporting BioPontis’ mission to bridge the gap between early-stage research and technologies being discovered and developed in academia and other research entities. AMRI will provide its services in small molecule discovery, development, and manufacturing in BioPontis’ drug discovery research programs. The agreement also supports the need for proof-of-concept data that is required in the current pharmaceutical company licensing environment. The goal of BioPontis Alliance is to identify promising early stage product opportunities and utilize a preferred network of CROs and leading research companies to apply appropriate expertise to develop these opportunities enough to attract pharmaceutical company licensing partners.
More info >> |
|
|
